Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Quidel Corporation discovers, develops, manufactures, and markets diagnostic healthcare products and solutions. The Company offers diagnostic solutions which help in the detection and diagnosis of critical diseases and other medical conditions, including infectious, women health, gastrointestinal, autoimmune, and bone health and thyroid diseases.
Website: quidel.com



Growth: Bad revenue growth rate -74.0%, there is slowdown compared to average historical growth rates 36.9%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +41.7%

Profitability: LTM EBITDA margin is negative, -58.1%. On average the margin is decreasing steadily. In the last quarter the company beat the estimated EPS, +20.8%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$0.15 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -4.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 55.5% higher than minimum and 81.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -1.1x by EV / Sales multiple

Key Financials (Download financials)

Ticker: QDEL
Share price, USD:  (-3.2%)16.05
year average price 25.27  


year start price 27.39 2025-07-26

max close price 35.38 2026-01-15

min close price 10.32 2026-05-15

current price 16.05 2026-07-25
Common stocks: 66 300 000

Dividend Yield:  0.0%
EV / Sales: 0.8x
Margin (EBITDA LTM / Revenue): -58.1%
Fundamental value created in LTM:
Market Cap ($m): 1 099
Net Debt ($m): 2 635
EV (Enterprise Value): 3 734
Price to Book: 0.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-03prnewswire.com

QuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie® Awards

2026-01-22prnewswire.com

Strengthening the blood supply: Awareness, challenges and donor impact

2026-01-21prnewswire.com

QuidelOrtho to Report Fourth Quarter and Full-Year 2025 Financial Results

2026-01-15zacks.com

Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now

2025-12-18prnewswire.com

Innovating Diagnostics and What's Next

2025-12-07fool.com

Why One Value Fund Just Bought $30 Million of a Diagnostics Stock Down 90% From Pandemic-Era Highs

2025-12-03seekingalpha.com

QuidelOrtho Corporation (QDEL) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

2025-11-06seekingalpha.com

QuidelOrtho Corporation (QDEL) Q3 2025 Earnings Call Transcript

2025-10-22prnewswire.com

QuidelOrtho to Report Third Quarter 2025 Financial Results

2025-10-16prnewswire.com

QuidelOrtho Showcases Leadership in Transfusion Medicine at AABB 2025
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-28 2025-06-29 2024-12-31 2024-09-29 2024-06-30 2024-03-31 2023-12-31 2023-10-01 2023-07-02 2023-04-02 2022-12-31 2022-10-02 2021-12-31 2020-12-31
symbol QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-06 2024-11-08 2024-08-01 2024-05-09 2023-11-02 2023-08-09 2023-05-04 2022-11-04
acceptedDate 2025-11-05 18:02:04 2025-08-05 18:11:59 2025-02-27 16:01:54 2024-11-07 18:03:52 2024-08-01 15:13:32 2024-05-08 18:04:23 2024-02-29 15:29:59 2023-11-01 18:04:39 2023-08-08 18:11:48 2023-05-04 16:09:15 2023-02-23 17:16:50 2022-11-03 20:40:53 2021-12-31 00:00:00 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 700M 615M 2 783M 727M 636M 710M 2 998M 744M 665M 846M 3 266M 784M 1 699M 1 662M
costOfRevenue 48M 387M 1 496M 375M 413M 432M 1 503M 376M 369M 398M 1 330M 376M 420M 313M
grossProfit 652M 228M 1 287M 352M 224M 278M 1 494M 368M 296M 449M 1 936M 408M 1 278M 1 349M
grossProfitRatio 0.932 0.371 0.485 0.351 0.391 0.495 0.446 0.53 0.52
researchAndDevelopmentExpenses 42M 46M 219M 56M 56M 59M 247M 62M 63M 62M 188M 66M 96M 84M
generalAndAdministrativeExpenses 0 0 0 0 0 0 748M 0 0 0 0 0 226M 67M
sellingAndMarketingExpenses 0 0 0 0 0 0 15M 0 0 0 0 0 14M 134M
sellingGeneralAndAdministrativeExpenses 187M 178M 767M 186M 188M 205M 763M 194M 179M 202M 621M 204M 240M 201M
otherExpenses 1 129M 5M 2 262M 95M -9M -8M 345M -4M -1 000 000 55M 284M 55M 37M 4M
operatingExpenses 1 357M 229M 3 247M 337M 254M 272M 1 355M 315M 299M 319M 1 093M 324M 372M 289M
costAndExpenses 1 405M 616M 4 744M 712M 667M 704M 2 859M 691M 668M 717M 2 422M 701M 793M 601M
interestIncome 0 3M 0 0 500 000 900 000 2M 1M 2M 1 000 000 1M 300 000 300 000 0
interestExpense 46M 46M 188M 50M 48M 46M 179M 38M 37M 37M 75M 30M 700 000 1M
depreciationAndAmortization 112M 110M 453M 113M 116M 115M 457M 51M 51M 78M 284M 51M 53M 49M
ebitda -599M -73M -1 490M 128M -13M 121M 607M 100M 48M 177M 1 094M 138M 953M 1 099M
ebitdaratio -0.855 -0.119 0.175 0.135 0.17 0.135 0.072 0.209 0.176
operatingIncome -705M -500 000 -1 961M 15M -30M 6M 139M 26M -27M 100M 844M 87M 906M 1 060M
operatingIncomeRatio -1.007 -0.001 0.021 -0.048 0.008 0.035 -0.04 0.118 0.112
totalOtherIncomeExpensesNet -52M -229M -171M -44M -45M -1 805M -168M -31M -25M -40M -108M -56M -6M -20M
incomeBeforeTax -757M -230M -2 132M -29M -163M -1 799M -29M -16M -64M 60M 736M 31M 900M 1 040M
incomeBeforeTaxRatio -1.081 -0.373 -0.04 -0.256 -2.535 -0.021 -0.097 0.071 0.04
incomeTaxExpense -24M 26M -80M -9M -15M -93M -19M -3M -11M 11M 187M 12M 196M 230M
netIncome -733M -255M -2 052M -20M -148M -1 706M -10M -13M -53M 49M 549M 19M 704M 810M
netIncomeRatio -1.047 -0.415 -0.027 -0.232 -2.404 -0.017 -0.08 0.058 0.024
eps -10.78 -3.77 -30.54 -0.3 -2.2 -25.5 -0.15 -0.19 -0.8 0.73 9.66 0.29 16.74 19.24
epsdiluted -10.78 -3.77 -0.3 -2.2 -25.5 -0.19 -0.8 0.73 0.28
weightedAverageShsOut 68M 68M 67M 67M 67M 67M 67M 67M 67M 67M 57M 67M 42M 42M
weightedAverageShsOutDil 68M 68M 67M 67M 67M 67M 67M 67M 67M 67M 57M 68M 43M 44M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-29 2023-02-23 2021-12-31 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -189M -177M -73M -400 000 -1M
ebit -1 943M 150M 810M 901M 1 050M
nonOperatingIncomeExcludingInterest -18M -11M 33M 5M 10M
netIncomeFromContinuingOperations -2 052M -10M 549M 704M 810M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 -445 000
bottomLineNetIncome -2 052M -10M 549M 704M 811M
epsDiluted -30.54 -0.15 9.56 16.43 18.6

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-28 2025-06-29 2024-12-29 2024-09-29 2024-06-30 2024-03-31 2023-12-31 2023-10-01 2023-07-02 2023-04-02 2023-01-01 2022-10-02 2021-12-31 2020-12-31
symbol QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-06 2024-11-08 2024-08-01 2024-05-09 2023-11-02 2023-08-09 2023-05-04 2022-11-04
acceptedDate 2025-11-05 18:02:04 2025-08-05 18:11:59 2025-02-27 16:01:54 2024-11-07 18:03:52 2024-08-01 15:13:32 2024-05-08 18:04:23 2024-02-29 15:29:59 2023-11-01 18:04:39 2023-08-08 18:11:48 2023-05-04 16:09:15 2023-02-23 17:16:50 2022-11-03 20:40:53 2021-12-31 00:00:00 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 98M 152M 98M 144M 107M 79M 119M 149M 179M 354M 293M 212M 803M 490M
shortTermInvestments 0 0 0 0 200 000 300 000 48M 44M 45M 43M 52M 52M 26M 0
cashAndShortTermInvestments 98M 152M 98M 144M 107M 79M 167M 193M 224M 397M 345M 264M 829M 490M
netReceivables 513M 397M 451M 334M 314M 476M 488M 331M 247M 275M 586M 417M 394M 529M
inventory 614M 579M 534M 577M 602M 583M 578M 552M 542M 529M 524M 536M 199M 114M
otherCurrentAssets 142M 154M 58M 355M 135M 75M 10M 295M 296M 299M 23M 1M 5M 2M
totalCurrentAssets 1 367M 1 282M 1 219M 1 413M 1 341M 1 212M 1 311M 1 371M 1 308M 1 499M 1 575M 1 445M 1 440M 1 142M
propertyPlantEquipmentNet 1 480M 1 472M 1 549M 1 539M 1 504M 1 622M 1 613M 1 542M 1 554M 1 541M 1 520M 1 425M 477M 211M
goodwill 0 711M 650M 771M 733M 735M 2 492M 2 443M 2 471M 2 491M 2 477M 2 358M 337M 337M
intangibleAssets 2 608M 2 661M 2 736M 2 796M 2 836M 2 887M 2 934M 2 977M 3 036M 3 079M 3 124M 3 224M 99M 122M
goodwillAndIntangibleAssets 2 608M 3 372M 3 385M 3 567M 3 569M 3 622M 5 426M 5 419M 5 507M 5 570M 5 601M 5 582M 436M 459M
longTermInvestments 13M 0 22M 0 500 000 500 000 7M 12M 25M 34M 21M 20M 38M 0
taxAssets 0 0 0 26M 25M 25M 26M 16M 16M 17M 16M 19M 20M 45M
otherNonCurrentAssets 207M 254M 249M 257M 250M 222M 180M 179M 141M 127M 123M 164M 20M 14M
totalNonCurrentAssets 4 308M 5 098M 5 205M 5 389M 5 348M 5 491M 7 253M 7 168M 7 242M 7 288M 7 281M 7 210M 990M 729M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 5 675M 6 379M 6 424M 6 801M 6 689M 6 703M 8 563M 8 539M 8 550M 8 787M 8 856M 8 656M 2 430M 1 871M
accountPayables 214M 219M 246M 247M 237M 250M 295M 253M 226M 242M 283M 242M 102M 86M
shortTermDebt 192M 564M 342M 405M 386M 190M 140M 193M 207M 208M 208M 208M 300 000 0
taxPayables 900 000 48M 5M 2M 4M 10M 29M 2M 2M 16M 52M 67M 77M 128M
deferredRevenue 34M 40M 34M 2M 40M 34M 37M 109M 84M 62M 76M 33M 2M 4M
otherCurrentLiabilities 327M 271M 97M 371M 266M 306M 128M 305M 273M 397M 156M 391M 66M 74M
totalCurrentLiabilities 768M 1 142M 999M 1 027M 932M 780M 834M 860M 790M 908M 1 007M 873M 324M 337M
longTermDebt 2 652M 2 229M 2 141M 2 341M 2 385M 2 241M 2 275M 2 451M 2 490M 2 563M 2 431M 2 645M 400 000 0
deferredRevenueNonCurrent 17M 0 17M 9M 16M 14M 0 14M 0 0 9M 0 0 -38M
deferredTaxLiabilitiesNonCurrent 80M 83M 77M 117M 128M 126M 192M 197M 200M 209M 213M 256M 0 38M
otherNonCurrentLiabilities 122M 133M 38M 129M 71M 235M 84M 52M 69M 111M 74M 2 506M 49M 101M
totalNonCurrentLiabilities 2 871M 2 444M 2 440M 2 587M 2 583M 2 616M 2 723M 2 712M 2 758M 2 883M 2 914M 2 988M 178M 202M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 159M 186M 198M 205M 207M 182M 200M 176M 181M 183M 211M 163M 139M 109M
totalLiabilities 3 639M 3 586M 3 439M 3 614M 3 516M 3 396M 3 557M 3 572M 3 548M 3 791M 3 921M 3 860M 501M 538M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 0 0 0 42 000
retainedEarnings -865M -132M 136M 314M 334M 482M 2 188M 2 181M 2 194M 2 247M 2 198M 2 168M 1 649M 945M
accumulatedOtherComprehensiveIncomeLoss -20M 16M -36M -4M -25M -26M -30M -53M -16M -59M -68M -145M 400 000 -431 000
othertotalStockholdersEquity 2 921M 2 909M 2 876M 2 864M 2 852M 2 839M 2 825M 2 809M 2 772M
totalStockholdersEquity 2 036M 2 793M 2 985M 3 187M 3 174M 3 308M 5 006M 4 967M 5 003M 4 997M 4 935M 4 795M 1 929M 1 333M
totalEquity 2 036M 2 793M 2 985M 3 187M 3 174M 3 308M 5 006M 4 967M 5 003M 4 997M 4 935M 4 795M 1 929M 1 333M
totalLiabilitiesAndStockholdersEquity 5 675M 6 379M 6 801M 6 689M 6 703M 8 539M 8 550M 8 787M 8 656M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 5 675M 6 379M 6 424M 6 801M 6 689M 6 703M 8 563M 8 539M 8 550M 8 787M 8 856M 8 656M 2 430M 1 871M
totalInvestments 13M 0 22M 0 500 000 500 000 56M 44M 45M 43M 73M 72M 64M 0
totalDebt 2 844M 2 793M 2 681M 2 756M 2 771M 2 613M 2 614M 2 644M 2 697M 2 770M 2 849M 2 852M 139M 109M
netDebt 2 746M 2 641M 2 583M 2 612M 2 664M 2 534M 2 495M 2 494M 2 519M 2 417M 2 556M 2 640M -664M -381M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-29 2023-02-23 2021-12-31 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 315M 350M 504M 378M 498M
otherReceivables 136M 139M 83M 16M 31M
prepaids 77M 67M 97M 15M 7M
totalPayables 272M 324M 344M 190M 216M
otherPayables 26M 29M 61M 88M 130M
accruedExpenses 223M 179M 198M 56M 35M
capitalLeaseObligationsCurrent 31M 27M 24M 10M 8M
capitalLeaseObligationsNonCurrent 167M 173M 186M 129M 101M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 2 885M 2 848M 2 804M 280M 388M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-28 2025-06-29 2024-12-29 2024-09-29 2024-06-30 2024-03-31 2023-12-31 2023-10-01 2023-07-02 2023-04-02 2023-01-01 2022-10-02 2021-12-31 2020-12-31
symbol QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL QDEL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-06 2024-11-08 2024-08-01 2024-05-09 2023-11-02 2023-08-09 2023-05-04 2022-11-04
acceptedDate 2025-11-05 18:02:04 2025-08-05 18:11:59 2025-02-27 16:01:54 2024-11-07 18:03:52 2024-08-01 15:13:32 2024-05-08 18:04:23 2024-02-29 15:29:59 2023-11-01 18:04:39 2023-08-08 18:11:48 2023-05-04 16:09:15 2023-02-23 17:16:50 2022-11-03 20:40:53 2021-12-31 00:00:00 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -733M -255M -2 052M -20M -148M -1 706M -10M -13M -53M 49M 549M 19M 704M 810M
depreciationAndAmortization 112M 110M 453M 113M 116M 115M 457M 113M 115M 114M 284M 104M 54M 49M
deferredIncomeTax -1 000 000 0 -99M 74M 300 000 -74M 0 -3M -11M 0 0 0 25M -20M
stockBasedCompensation 11M 13M 42M 12M 11M 9M 52M 14M -500 000 11M 48M 13M 25M 21M
changeInWorkingCapital -135M -75M -159M 9M -130M -86M -195M -69M -30M 129M -53M -176M -3M -251M
accountsReceivables -113M 23M 5M -17M -2M 26M 160M -90M 27M 187M 150M -51M 119M -402M
inventory -39M -50M -134M -16M -58M -38M -212M -60M -11M -37M -117M -62M -85M -55M
accountsPayables 8M -22M -23M 7M -13M -11M 3M 29M -14M -21M 24M 56M 10M 52M
otherWorkingCapital 10M -26M -7M 34M -57M -64M -146M 53M -33M -129M -110M -119M -47M 154M
otherNonCashItems 701M 160M 1 898M -70M 369M 1 929M -24M -2M -50M -114M 58M 29M -34 000 21M
netCashProvidedByOperatingActivities -46M -47M 83M 118M -98M -700 000 280M 42M -31M 189M 885M -10M 806M 630M
investmentsInPropertyPlantAndEquipment -49M 7M -195M -47M -35M -66M -209M -43M -51M 20M -141M -31M -293M -65M
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 -1 511M 0 0 0
purchasesOfInvestments 0 0 -7M 0 0 -7M -60M 0 -19M -32M -64M -16M -67M 0
salesMaturitiesOfInvestments 0 0 63M 0 0 63M 78M 14M 26M 28M 53M 11M 4M 0
otherInvestingActivites -5M -40M -10M 0 -10M 8M 3M -86M 5M
netCashUsedForInvestingActivites -54M -33M -57M -35M -20M -21M -42M -69M -30M
debtRepayment 44M 106M -26M 161M -13M -52M -72M -52M -52M
commonStockIssued 3M 100 000 400 000 4M 500 000 800 000 6M 2M 800 000
commonStockRepurchased 0 0 0 0 0 -6M -7M -500 000 0 0 -74M -74M -103M -44M
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -900 000 -3M -400 000 -3M -6M 3M -33M -10M -800 000
netCashUsedProvidedByFinancingActivities 46M 103M -26M 163M -19M -49M -100M -60M -126M
effectOfForexChangesOnCash -200 000 1 000 000 -3M 1M -800 000 -1M -1M -1M -3M 600 000 -2M -2M -352 000 1M
netChangeInCash -54M 25M -21M 37M 29M -40M -174M -30M -175M 61M -509M -167M 313M 437M
cashAtEndOfPeriod 98M 152M 99M 144M 107M 79M 120M 150M 180M 355M 294M 213M 803M 490M
cashAtBeginningOfPeriod 152M 127M 120M 107M 79M 119M 294M 180M 355M 294M 803M 381M 490M 53M
operatingCashFlow -46M -47M 83M 118M -98M -700 000 280M 42M -31M 189M 885M -10M 806M 630M
capitalExpenditure -49M 7M -195M -47M -35M -66M -209M -43M -51M -66M -141M -31M -293M -65M
freeCashFlow -95M -40M -112M 71M -133M -67M 71M -2M -82M 189M 744M -40M 513M 565M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-29 2023-02-23 2021-12-31 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -11M 4M 18M 37M 2M
netCashProvidedByInvestingActivities -150M -188M -1 644M -320M -63M
netDebtIssuance 53M -226M 346M -300 000 -44M
longTermNetDebtIssuance 55M -228M 346M -300 000 -44M
shortTermNetDebtIssuance -2M 2M 0 0 0
netStockIssuance 5M 4M -48M -96M -38M
netCommonStockIssuance 5M 4M -48M -96M -34M
commonStockIssuance 5M 12M 26M 8M 10M
netPreferredStockIssuance 0 0 0 12 000 -4M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -10M -44M -46M -77M -48M
netCashProvidedByFinancingActivities 49M -266M 252M -173M -130M
incomeTaxesPaid 178M 87M 265M 236M 110M
interestPaid 178M 150M 95M 0 500 000

Earning call transcript

2025 q3
2025-11-06 ET (fiscal 2025 q3)
2025 q2
2025-08-06 ET (fiscal 2025 q2)
2025 q1
2025-05-07 ET (fiscal 2025 q1)
2024 q4
2025-02-12 ET (fiscal 2024 q4)
2024 q3
2024-11-07 ET (fiscal 2024 q3)
2024 q2
2024-07-31 ET (fiscal 2024 q2)
2024 q1
2024-05-08 ET (fiscal 2024 q1)
2023 q4
2024-02-13 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-15 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-06-02 11:12 ET
QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies
2026-05-21 13:18 ET
When Blood Compatibility Becomes a Pregnancy Risk
2026-05-20 ET
QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences
2026-05-05 ET
QuidelOrtho Reports First Quarter 2026 Financial Results
2026-04-23 ET
Understanding and Addressing Syphilis Trends - and What's Being Missed
2026-04-20 ET
QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics
2026-04-15 ET
QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance
2026-03-24 ET
Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer
2026-02-19 14:17 ET
Faster Cardiac Answers with High‑Sensitivity Troponin
2026-02-18 21:05 ET
QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference
2026-02-11 21:05 ET
QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results
2026-02-03 12:12 ET
QuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie® Awards
2026-01-22 12:12 ET
Strengthening the blood supply: Awareness, challenges and donor impact
2026-01-21 12:00 ET
QuidelOrtho to Report Fourth Quarter and Full-Year 2025 Financial Results
2025-12-18 14:17 ET
Innovating Diagnostics and What's Next
2025-11-24 12:00 ET
QuidelOrtho To Participate In Upcoming Investor Conferences
2025-11-20 14:00 ET
The Power of Prevention: Detecting Diabetes Before It Strikes
2025-11-05 ET
QuidelOrtho Reports Third Quarter 2025 Financial Results
2025-11-03 ET
QuidelOrtho Receives FDA 510(k) Clearance for VITROS™ Immunodiagnostic Products hs Troponin I Assay
2025-10-23 ET
Informatics Illuminated: Science Bytes Podcast Explores the Power Behind Smarter Diagnostics
2025-10-22 ET
QuidelOrtho to Report Third Quarter 2025 Financial Results
2025-10-16 ET
QuidelOrtho Showcases Leadership in Transfusion Medicine at AABB 2025
2025-09-25 ET
Through Shades of Illness: Science Bytes Podcast Discusses Why Testing Matters
2025-09-22 ET
QuidelOrtho Announces Availability of QUICKVUE™ Influenza + SARS Test for Professional Use
2025-08-28 ET
QuidelOrtho to Participate in the Baird 2025 Global Healthcare Conference
2025-08-21 ET
QuidelOrtho Completes Debt Refinancing
2025-08-21 ET
Science Bytes Podcast Explores How Diagnostics Can Help Protect Students and Communities
2025-08-19 ET
QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development
2025-08-13 ET
QuidelOrtho Launches Certified Analyzer Program
2025-08-05 ET
QuidelOrtho Reports Second Quarter 2025 Financial Results
2025-07-29 ET
QuidelOrtho Recognized with Three Awards in 2025 IMV ServiceTrak™
2025-07-24 ET
Urgent Need for Early Detection in Drug Overdose Cases Highlighted in New Podcast
2025-07-22 ET
QuidelOrtho to Report Second Quarter 2025 Financial Results
2025-07-17 ET
Real Labs, Actual Decisions With Actionable Six Sigma Metrics
2025-07-14 ET
QUIDELORTHO AND BÜHLMANN LABORATORIES AG ANNOUNCE AVAILABILITY OF FECAL CALPROTECTIN (FCAL®) TURBO AND FECAL PANCREATIC ELASTASE (FPELA®) TURBO ASSAYS ON VITROS™ SYSTEMS AS A MICROTIP™ PARTNERSHIP ASSAY (MPA)
2025-07-07 ET
QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs
2025-06-03 ET
QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics
2025-05-22 ET
QuidelOrtho to Participate in Upcoming Investor Conferences
2025-05-07 ET
QuidelOrtho Reports First Quarter 2025 Financial Results
2025-04-23 ET
QuidelOrtho to Report First Quarter 2025 Financial Results
2025-03-10 ET
QuidelOrtho® Introduces Results Manager™ System
2025-02-24 ET
QuidelOrtho to Participate in the 46th Annual Raymond James Institutional Investor Conference
2025-02-12 ET
QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results
2025-01-13 ET
QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024
2024-12-31 ET
QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-10 ET
QuidelOrtho Announces Appointment of Two Independent Directors to its Board
2024-11-19 ET
QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group
2024-11-19 ET
QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group
2024-11-07 ET
QuidelOrtho Reports Third Quarter 2024 Financial Results
2024-10-28 11:00 ET
QuidelOrtho to Participate in Three Upcoming Investor Conferences
2024-10-17 11:00 ET
QuidelOrtho to Report Third Quarter 2024 Financial Results
2024-10-09 11:00 ET
QuidelOrtho Announces New R&D Executive Leader
2024-09-10 11:00 ET
QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer
2024-08-29 11:00 ET
VITROS® Syphilis Assay Now Available on VITROS 3600 Immunodiagnostic System, VITROS 5600 and VITROS XT 7600 Integrated Systems in the U.S.
2024-08-19 11:00 ET
QuidelOrtho to Participate in Upcoming Investor Conferences
2024-07-31 20:05 ET
QuidelOrtho Reports Second Quarter 2024 Financial Results
2024-07-17 11:00 ET
QuidelOrtho to Report Second Quarter 2024 Financial Results
2024-06-10 23:09 ET
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important June 11 Deadline in Securities Class Action - QDEL
2024-05-23 11:00 ET
QuidelOrtho to Participate in 44th Annual William Blair Growth Stock Conference
2024-05-15 20:05 ET
QuidelOrtho Opens New Distribution Center in Pedricktown, NJ
2024-05-08 20:05 ET
QuidelOrtho Reports First Quarter 2024 Financial Results
2024-05-02 12:00 ET
QuidelOrtho Appoints Brian J. Blaser as President and Chief Executive Officer
2024-04-17 11:00 ET
QuidelOrtho To Report First Quarter 2024 Financial Results
2024-04-16 13:00 ET
Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain Executives
2024-04-12 22:00 ET
Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Company and Certain Executives
2024-04-10 11:00 ET
QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay
2024-04-02 13:00 ET
QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test
2024-02-26 21:30 ET
QuidelOrtho to Participate in 45th Annual Raymond James Institutional Investor Conference
2024-02-21 12:30 ET
QuidelOrtho Announces Changes in Executive Leadership
2024-02-13 21:05 ET
QuidelOrtho Reports Fourth Quarter and Full-Year 2023 Financial Results
2024-01-23 12:00 ET
QuidelOrtho to Report Fourth Quarter and Full-year 2023 Financial Results
2023-12-22 12:00 ET
QuidelOrtho to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-20 21:05 ET
QuidelOrtho Receives 510(K) Clearance for Savanna® Multiplex Molecular Platform and Savanna® HSV 1+2/VZV PCR Assay
2023-11-16 22:05 ET
QuidelOrtho to Participate in the Evercore ISI Conference
2023-11-01 20:05 ET
QuidelOrtho Reports Third Quarter 2023 Financial Results
2023-10-17 19:43 ET
Powerful Lyme Disease Awareness PSA Featuring Christopher Meloni Illuminates Times Square
2023-10-12 11:00 ET
QuidelOrtho Reports Preliminary Revenue Results for the Third Quarter 2023
2023-09-21 20:05 ET
QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA
2023-08-28 20:05 ET
QuidelOrtho to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-08 20:30 ET
QuidelOrtho Reports Second Quarter 2023 Financial Results
2023-07-25 20:00 ET
QuidelOrtho Ranks No. 1 in Customer Satisfaction for Six Years in a Row
2023-07-24 19:00 ET
QuidelOrtho Partners With BYG4lab® to Strengthen Informatics Offerings
2023-07-18 20:05 ET
QuidelOrtho to Report Second Quarter 2023 Financial Results
2023-05-23 11:00 ET
QuidelOrtho to Participate in William Blair 43rd Annual Growth Stock Conference
2023-05-03 20:05 ET
QuidelOrtho Reports First Quarter 2023 Financial Results
2023-04-13 20:05 ET
QuidelOrtho Reports Preliminary Revenue Results for the First Quarter 2023
2023-03-28 15:05 ET
QuidelOrtho Announces the Formation of the International QuidelOrtho Women’s Leadership Network (QWLN)
2023-03-08 21:05 ET
QuidelOrtho Receives De Novo FDA Authorization for Sofia® 2 SARS Antigen+ FIA
2023-03-02 19:01 ET
QuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor Conference
2023-02-27 16:00 ET
ImageMover and QuidelOrtho Partner to Simplify Test-to-Treat Process for Pharmacies
2023-02-15 21:05 ET
QuidelOrtho Reports Fourth Quarter and Full Year 2022 Financial Results
2023-01-06 21:05 ET
QuidelOrtho Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022
2022-12-28 12:00 ET
QuidelOrtho to Present at the J.P. Morgan Healthcare Conference
2022-12-19 20:15 ET
Health Canada Grants License for Quidel® TriageTrue® High-Sensitivity Troponin I Test to Aid in the Diagnosis of Myocardial Infarction
2022-12-16 16:05 ET
QuidelOrtho and Runda Medical Form Joint Venture to Develop and Manufacture Assays for VITROS® Platform
2022-12-12 21:54 ET
QuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles
2022-11-30 21:05 ET
QuidelOrtho to Host Investor Day on December 13, 2022
2022-11-02 20:05 ET
QuidelOrtho Reports Third Quarter 2022 Financial Results
2022-10-12 20:05 ET
QuidelOrtho Reports Preliminary Revenue Results for Third Quarter 2022
2022-10-04 13:00 ET
Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel Corporation
2022-10-04 13:00 ET
Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel Corporation
2022-09-06 12:00 ET
QuidelOrtho to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
2022-09-01 16:00 ET
Quidel and World Champion Los Angeles Rams Partner to Combat COVID-19 and Promote Health Awareness in the L.A. Community
2022-08-24 13:00 ET
Bacterial Biofilms, Responsible for Up to 75% of All Infectious Diseases in America, Explored in New Webinar From Quidel Corporation
2022-08-17 20:30 ET
QuidelOrtho Announces $300 Million Share Repurchase Authorization
2022-08-04 20:10 ET
QuidelOrtho Reports Second Quarter 2022 Financial Results
2022-07-26 13:35 ET
ORTHO RANKS NO. 1 IN CUSTOMER SATISFACTION FOR 5 YEARS IN A ROW
2022-07-18 20:05 ET
QuidelOrtho to Report Second Quarter 2022 Financial Results on August 4, 2022
2022-06-21 23:00 ET
Quidel Corporation and the American Heart Association join forces to Advance Education and Awareness of Heart Disease in San Diego County
2022-06-09 13:00 ET
QUIDEL CORP.—DEVELOPER OF ONLY FDA-CLEARED FIA RAPID POINT-OF-CARE DIAGNOSTIC LYME DISEASE TEST—TO PARTNER WITH RENOWNED GLOBAL LYME ALLIANCE TO DRAMATICALLY HEIGHTEN LYME DISEASE AWARENESS
2022-06-09 13:00 ET
Quidel Corp.—Developer of Only FDA-Cleared FIA Rapid Point-of-Care Diagnostic Lyme Disease Test—To Partner With Renowned Global Lyme Alliance to Dramatically Heighten Lyme Disease Awareness
2022-05-27 13:00 ET
QuidelOrtho Formed by the Completion of Transaction Combining Quidel and Ortho Clinical Diagnostics
2022-05-26 16:24 ET
Quidel and Ortho Announce Expected Closing of Ortho Transaction
2022-05-26 16:05 ET
Quidel and Ortho Announce Expected Closing of Ortho Transaction
2022-05-16 20:45 ET
Ortho Clinical Diagnostics Shareholders Approve Quidel Transaction
2022-05-16 20:45 ET
Quidel Announces Stockholder Approval of Ortho Acquisition and Business Combination
2022-05-04 20:10 ET
Quidel Reports First Quarter 2022 Financial Results
2022-04-12 22:00 ET
Quidel to Hold Fiscal First Quarter 2022 Financial Results Conference Call on May 4th, 2022
2022-04-07 20:10 ET
Quidel Announces Preliminary Revenue for First Quarter 2022
2022-02-28 23:30 ET
Quidel to Present at Raymond James 43rd Annual Institutional Investors Conference
2022-02-17 21:10 ET
Quidel Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-01 21:10 ET
Quidel to Hold Fiscal Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 17th, 2022
2022-01-06 21:10 ET
Quidel Announces Preliminary Revenue for Fourth Quarter 2021
2022-01-05 14:00 ET
The Signs, Diagnosis and Treatment of Lyme Disease Discussed as Part of New, On-Demand Webinar Hosted by Industry-Leading Quidel Corporation
2022-01-05 14:00 ET
The Signs, Diagnosis and Treatment of Lyme Disease Discussed as Part of New, On-Demand Webinar Hosted by Industry-Leading Quidel Corporation
2022-01-04 22:00 ET
Quidel to Present at 40th Annual J.P. Morgan Healthcare Conference
2021-12-28 23:00 ET
Quidel’s Antigen Tests Detect the Omicron Variant
2021-12-23 12:00 ET
Quidel Corporation Signs Definitive Agreement to Acquire Ortho Clinical Diagnostics
2021-12-15 21:10 ET
Quidel Announces Sponsorship and Community Partnership With the Chicago Blackhawks
2021-12-14 14:00 ET
Series of Infographics From Quidel Corporation Helps Educate Consumers on the Characteristics, Warning Signs and Prevalence of Lyme Disease
2021-12-14 14:00 ET
Series of Infographics From Quidel Corporation Helps Educate Consumers on the Characteristics, Warning Signs and Prevalence of Lyme Disease
2021-11-30 21:10 ET
Quidel Statement on the Omicron Variant
2021-11-19 23:00 ET
Quidel Presents at 33rd Annual Piper Sandler Healthcare Conference
2021-11-04 20:10 ET
Quidel Reports Third Quarter 2021 Financial Results
2021-11-02 16:44 ET
Quidel Corporation to Sponsor Distinguished Speaker Series Conducted by the Bay Area Lyme Foundation
2021-11-02 16:42 ET
Quidel Corporation to Sponsor Distinguished Speaker Series Conducted by the Bay Area Lyme Foundation
2021-10-20 21:30 ET
Quidel to Hold Fiscal Third Quarter 2021 Financial Results Conference Call on November 4th, 2021
2021-10-18 19:11 ET
Pediatric Lyme Disease—‘An Epidemic Within a Pandemic!’—to be Focus of Free Webinar Hosted by Quidel Corporation Oct. 21
2021-10-18 18:56 ET
Pediatric Lyme Disease—'An Epidemic Within a Pandemic!’—to be Focus of Free Webinar Hosted by Quidel Corporation Oct. 21
2021-10-07 20:10 ET
Quidel Announces Preliminary Revenue for Fiscal Third Quarter 2021
2021-09-01 20:10 ET
Quidel to Bring QuickVue® At-Home OTC COVID-19 Tests To CVS Pharmacy
2021-08-10 13:00 ET
LivLyme Foundation Founder Olivia Goodreau to Discuss Perils of Lyme Disease in Free Webinar Hosted by Industry-Leading Quidel Corporation
2021-08-10 13:00 ET
LivLyme Foundation Founder Olivia Goodreau to Discuss Perils of Lyme Disease in Free Webinar Hosted by Industry-Leading Quidel Corporation
2021-08-05 20:10 ET
Quidel Reports Second Quarter 2021 Financial Results
2021-07-26 12:30 ET
Quidel Announces Agreement With Beckman Coulter That Terminates Ongoing Litigation and Transitions BNP Business to Beckman Coulter
2021-07-19 14:30 ET
State of Delaware Selects Quidel for COVID-19 Testing Program at Schools
2021-07-14 20:10 ET
Quidel to Hold Fiscal Second Quarter 2021 Financial Results Conference Call on August 5th, 2021
2021-07-12 13:15 ET
Quidel Receives CE Mark for Savanna® Multiplex Molecular Analyzer and Respiratory Viral Panel
2021-07-12 13:00 ET
New Website Created by Quidel Corporation Provides Consumers With Information and Easy-to-Understand Answers Regarding Lyme Disease
2021-07-12 13:00 ET
New Website Created by Quidel Corporation Provides Consumers With Information and Easy-to-Understand Answers Regarding Lyme Disease
2021-06-29 13:00 ET
Public Service Campaign From Quidel Corporation Directed Toward Heightening Awareness Among Summer Camps of the Dangers of Lyme Disease
2021-06-29 13:00 ET
Public Service Campaign From Quidel Corporation Directed Toward Heightening Awareness Among Summer Camps of the Dangers of Lyme Disease
2021-06-24 17:07 ET
With Lyme Disease on the Rise Nationwide, Quidel Corporation Urges Early Testing With Its Rapid Point-of-Care Test
2021-06-24 17:04 ET
With Lyme Disease on the Rise Nationwide, Quidel Corporation Urges Early Testing With Its Rapid Point-of-Care Test
2021-06-11 20:10 ET
Quidel Receives Amended Emergency Use Authorization for New Sofia® Q Rapid Antigen Test Device
2021-06-10 20:45 ET
Quidel to Present Virtually at Raymond James Human Health Innovation Conference 2021
2021-05-24 21:10 ET
Quidel to Present Virtually at William Blair 41st Annual Growth Stock Conference
2021-05-24 20:10 ET
Health Canada Approves Quidel’s Sofia® SARS Antigen FIA Test for Screening of Asymptomatic Populations With Serial Testing
2021-05-14 20:10 ET
Quidel’s QuickVue® At-Home OTC COVID-19 Test Now Available for Sale Through Amazon
2021-05-06 20:10 ET
Quidel Reports First Quarter 2021 Financial Results
2021-05-06 00:30 ET
Quidel Forms Retail Collaboration With Walgreens for Over-the-Counter Sale of QuickVue® At-Home OTC COVID-19 Tests
2021-05-04 22:00 ET
Quidel to Present Virtually at the BofA Securities 2021 Health Care Conference
2021-04-27 13:00 ET
Teaching Doctors Nationwide How to Recognize and Differentiate Between Lyme Disease, COVID-19 and the Flu in Quidel-Hosted May 5 Webinar
2021-04-27 13:00 ET
Teaching Doctors Nationwide How to Recognize and Differentiate Between Lyme Disease, COVID-19 and the Flu in Quidel-Hosted May 5 Webinar
2021-04-26 23:00 ET
Quidel to Hold Fiscal First Quarter 2021 Financial Results Conference Call on May 6th, 2021
2021-04-22 20:32 ET
Quidel Signs Retail Distribution Agreement to Increase Access to At-Home COVID-19 Testing
2021-04-22 20:30 ET
Quidel Announces Preliminary Revenue for First Quarter 2021
2021-04-13 12:00 ET
Quidel Corporation Partners With the Bay Area Lyme Foundation to Heighten Public Awareness of Lyme Disease
2021-04-13 12:00 ET
Quidel Corporation Partners With the Bay Area Lyme Foundation to Heighten Public Awareness of Lyme Disease
2021-04-06 14:30 ET
Quidel Taps ICS to Collaborate on Next-Gen Multiplex Molecular Diagnostic Instruments for SARS-CoV-2/COVID Pathogen Detection
2021-04-05 12:00 ET
Start of Lyme Disease Season Provides Heightened Risks for Americans Wanting to Go Outdoors After a Year of COVID-19 Restrictions
2021-04-05 12:00 ET
Start of Lyme Disease Season Provides Heightened Risks for Americans Wanting to Go Outdoors After a Year of COVID-19 Restrictions
2021-04-02 00:02 ET
Quidel’s Sofia® SARS Antigen Test Receives Emergency Use Authorization for Screening Use With Serial Testing
2021-04-01 23:30 ET
Quidel Partners With San Diego Padres Organization for COVID-19 Testing
2021-04-01 03:30 ET
Quidel Supports New NIH, CDC Public Health Initiative for At-home COVID-19 Testing
2021-04-01 03:00 ET
Quidel’s QuickVue® At-Home OTC COVID-19 Test Receives Emergency Use Authorization for Screening Use With Serial Testing
2021-03-18 22:00 ET
Quidel Corporation Applauds Biden Administration Plan to Expand COVID-19 Testing
2021-03-01 16:51 ET
Quidel Receives Emergency Use Authorization for QuickVue® At-Home COVID-19 Test
2021-02-22 21:10 ET
Quidel to Present at Upcoming Conferences
2021-02-18 21:10 ET
Quidel Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-03 21:10 ET
Quidel Opens New Manufacturing Facility to Mass Produce QuickVue® Rapid Antigen Tests for COVID-19
2021-01-28 21:10 ET
Quidel to Hold Fiscal Fourth Quarter and Full Year 2020 Financial Results Conference Call on February 18th, 2021
2021-01-07 19:15 ET
Quidel Announces Preliminary Revenue for Fourth Quarter 2020; Will Present Virtually at 39th Annual J.P. Morgan Healthcare Conference
2020-12-23 18:30 ET
Quidel Receives Emergency Use Authorization for Moderately Complex Solana® SARS Molecular Test for COVID-19 Diagnosis
2020-12-21 13:30 ET
Quidel Receives Emergency Use Authorization for QuickVue® SARS Rapid Antigen Test for COVID-19 Diagnosis
2020-12-10 23:00 ET
Quidel Corporation CEO Douglas Bryant Named Executive of the Year in MedTech Dive Awards For 2020
2020-11-19 15:00 ET
Quidel Corporation Hosts Upcoming Webinar to Help Health Professionals Distinguish Lyme Disease, Flu and COVID-19 During Frightening Respiratory Season
2020-11-19 15:00 ET
Quidel Corporation Hosts Upcoming Webinar to Help Health Professionals Distinguish Lyme Disease, Flu and COVID-19 During Frightening Respiratory Season
2020-11-10 23:00 ET
Quidel to Present at Upcoming Conferences
2020-11-10 16:00 ET
Quidel Corporation Triple Winner in International MarCom Awards Competition
2020-11-10 15:00 ET
Quidel Corporation Triple Winner in International MarCom Awards Competition
2020-11-03 21:10 ET
Quidel to Host Virtual Investor Day on November 12, 2020
2020-10-29 20:10 ET
Quidel Reports Third Quarter 2020 Financial Results
2020-10-22 12:00 ET
Quidel Corporation Joins Global Lyme Alliance as Sponsor for the GLA ‘Fight Lyme With Avril Lavigne and Friends’ Virtual Concert Oct. 24
2020-10-22 12:00 ET
Quidel Corporation Joins Global Lyme Alliance as Sponsor for the GLA 'Fight Lyme With Avril Lavigne and Friends' Virtual Concert Oct. 24
2020-10-19 20:10 ET
Quidel to Hold Third Fiscal Quarter 2020 Financial Results Conference Call on October 29th, 2020
2020-10-02 23:15 ET
Quidel Receives Emergency Authorization for First Rapid Antigen “ABC Test”: A Combination Diagnostic Assay for Influenza A+B and COVID-19
2020-10-01 13:00 ET
Quidel Announces Preliminary Revenue for Third Quarter 2020
2020-09-28 22:10 ET
Quidel Corporation Statement on President Trump’s Announcement of Coronavirus Testing Strategy
2020-08-27 18:46 ET
Quidel Provides Business Update at 13th Annual Piper Sandler Med-Tech and Diagnostic California Bus Tour; Another SARS Antigen Entrant Does Not Change Quidel’s Strategy
2020-08-27 18:32 ET
Quidel to Present Today at 13th Annual Piper Sandler Med-Tech and Diagnostics California Bus Tour
2020-08-25 15:00 ET
Webinar Discussing How Lyme Disease Affects Children to Be Held Aug. 27 and Hosted by Quidel Corporation
2020-08-20 18:30 ET
Quidel Concludes Sofia® SARS Antigen Investigation From Vermont
2020-08-20 01:30 ET
Quidel to Update Packaging of Point-of-Care Sofia® SARS Antigen Test for COVID-19 to Include Either Nasal or Nasopharyngeal Swabs
2020-08-12 22:00 ET
Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Health Canada Authorization
2020-08-10 22:38 ET
State of Maryland Allows Point-of-Care Testing for COVID-19; Quidel Expands Training Program
2020-07-31 15:30 ET
Quidel Receives Preliminary Contract Leading to Definitive Agreement for $71 Million Under NIH’s RADx-ATP Program to Accelerate the Expansion of Its Manufacturing Capacity for Sofia® SARS-CoV-2 Antigen Detection Test for Rapid Diagnosis of COVID-19
2020-07-30 20:10 ET
Quidel Reports Second Quarter 2020 Financial Results
2020-07-29 20:10 ET
CORRECTING and REPLACING Quidel to Present Virtually at the Canaccord Genuity 40th Annual Growth Conference
2020-07-22 15:00 ET
Published National Findings in Lyme Disease Testing to Be Discussed on July 30 Webinar Hosted by Quidel Corporation
2020-07-18 03:00 ET
Quidel’s Sofia® SARS Antigen FIA Updates EUA Performance Data to 96.7% PPA Versus PCR; Product Supports U.S. Initiatives to Expand Access to COVID-19 Testing in Nursing Homes; Receives CE Mark for Use With Sofia® and Sofia® 2 Instruments
2020-07-13 22:10 ET
Quidel to Hold Second Fiscal Quarter 2020 Financial Results Conference Call on July 30th, 2020
2020-07-06 21:00 ET
Quidel Announces Preliminary Revenue for Second Quarter 2020
2020-06-11 22:49 ET
Quidel Receives BARDA Funding to Develop Point-of-Care Diagnostic Assay That Includes COVID-19
2020-06-11 15:30 ET
Quidel Announces Jack Schuler Will Retire From Quidel’s Board of Directors
2020-06-09 23:00 ET
Quidel Receives Amended Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay Using Sofia 1 Instrument
2020-05-26 20:10 ET
Quidel to Present Virtually at William Blair 40th Annual Growth Stock Conference
2020-05-19 00:30 ET
Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Emergency Use Authorization and CE Mark for Molecular Detection of COVID-19, Without Extraction Step
2020-05-09 01:00 ET
Quidel Receives Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay
2020-05-06 20:10 ET
Quidel Reports First Quarter 2020 Financial Results
2020-04-29 21:00 ET
Quidel to Present Virtually at the BofA Securities 2020 Health Care Conference
2020-04-22 21:00 ET
Quidel’s Lyra® Direct SARS-CoV-2 Assay Submitted for Emergency Use Authorization for Molecular Detection of COVID-19, Without Extraction Step
2020-04-21 20:10 ET
Quidel to Hold First Quarter 2020 Financial Results Conference Call on May 6th, 2020
2020-03-26 00:45 ET
Quidel’s Lyra® SARS-CoV-2 Assay Receives Authorization for Expanded Use for Molecular Detection of COVID-19; Also Receives CE Mark, Health Canada Authorization
2020-03-18 00:30 ET
Quidel Receives Emergency Use Authorization for Molecular COVID-19 Diagnostic Assay
2020-02-18 21:10 ET
Quidel to Present at Upcoming Conferences
2020-02-12 21:10 ET
Quidel Reports Fourth Quarter and Full Year 2019 Financial Results
2020-01-28 21:10 ET
Quidel to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on February 12th, 2020
2020-01-09 23:00 ET
Quidel Announces Preliminary Revenue for Fourth Quarter 2019
2019-11-14 23:00 ET
Quidel to Present at Upcoming Conferences
2019-10-30 20:10 ET
Quidel Reports Third Quarter 2019 Financial Results
2019-10-17 22:00 ET
Quidel to Hold Third Quarter 2019 Financial Results Conference Call on October 30th, 2019

SEC forms

Show financial reports only

SEC form 10
2026-05-05 21:46 ET
Quidel published news for 2026 q1
SEC form 8
2026-05-05 20:07 ET
Quidel published news for 2026 q1
SEC form 8
2026-05-05 20:07 ET
Quidel published news for 2026 q1
SEC form 8
2026-04-15 20:15 ET
Quidel published news for 2026 q1
SEC form 8
2026-04-15 20:15 ET
Quidel published news for 2026 q1
SEC form 10
2026-02-19 02:45 ET
Quidel published news for 2025 q4
SEC form 8
2026-02-11 21:07 ET
Quidel reported for 2025 q4
SEC form 8
2026-02-11 21:07 ET
Quidel published news for 2025 q4
SEC form 8
2025-11-10 08:02 ET
Quidel published news for 2025 q3
SEC form 8
2025-11-10 08:02 ET
Quidel published news for 2025 q3
SEC form 10
2025-11-05 23:02 ET
Quidel published news for 2025 q3
SEC form 8
2025-11-05 16:08 ET
Quidel published news for 2025 q3
SEC form 8
2025-11-05 16:08 ET
Quidel reported for 2025 q3
SEC form 10
2025-08-05 22:11 ET
Quidel published news for 2025 q2
SEC form 8
2025-08-05 20:11 ET
Quidel published news for 2025 q2
SEC form 8
2025-08-05 20:11 ET
Quidel reported for 2025 q2
SEC form 10
2025-05-08 00:00 ET
Quidel published news for 2025 q1
SEC form 10
2025-05-07 21:45 ET
Quidel published news for 2025 q1
SEC form 8
2025-05-07 20:07 ET
Quidel reported for 2025 q1
SEC form 8
2025-05-07 20:07 ET
Quidel published news for 2025 q1
SEC form 8
2025-03-04 21:15 ET
Quidel published news for 2024 q4
SEC form 8
2025-03-04 21:15 ET
Quidel published news for 2024 q4
SEC form 10
2025-02-27 21:01 ET
Quidel reported for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Quidel reported for 2024 q4
SEC form 8
2025-02-12 16:06 ET
Quidel published news for 2024 q4
SEC form 8
2025-02-12 16:06 ET
Quidel reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Quidel published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Quidel published news for 2024 q4
SEC form 10
2024-11-07 18:03 ET
Quidel published news for 2024 q3
SEC form 8
2024-11-07 16:08 ET
Quidel reported for 2024 q3
SEC form 8
2024-11-07 16:08 ET
Quidel published news for 2024 q3
SEC form 10
2024-08-01 15:13 ET
Quidel published news for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Quidel published news for 2024 q2
SEC form 8
2024-07-31 16:08 ET
Quidel published news for 2024 q2
SEC form 8
2024-07-31 16:08 ET
Quidel reported for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Quidel published news for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Quidel published news for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Quidel reported for 2024 q1
SEC form 10
2024-02-29 00:00 ET
Quidel reported for 2023 q4
SEC form 8
2024-02-13 00:00 ET
Quidel published news for 2023 q4
SEC form 8
2024-02-13 00:00 ET
Quidel published news for 2023 q4
SEC form 10
2023-11-02 00:00 ET
Quidel published news for 2023 q3
SEC form 10
2023-11-01 18:04 ET
Quidel published news for 2023 q3
SEC form 8
2023-11-01 16:12 ET
Quidel reported for 2023 q3
SEC form 8
2023-10-12 00:00 ET
Quidel published news for 2023 q3
SEC form 10
2023-08-09 00:00 ET
Quidel published news for 2023 q2
SEC form 10
2023-08-08 18:11 ET
Quidel published news for 2023 q2
SEC form 6
2023-08-08 17:00 ET
Quidel reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Quidel published news for 2023 q2
SEC form 10
2023-05-04 00:00 ET
Quidel published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
Quidel published news for 2023 q1
SEC form 6
2023-04-13 16:22 ET
Quidel published news for 2023 q1
SEC form 8
2023-04-13 00:00 ET
Quidel published news for 2023 q1
SEC form 6
2023-04-10 16:33 ET
Quidel published news for 2023 q1
SEC form 10
2023-02-23 17:16 ET
Quidel reported for 2022 q4
SEC form 10
2023-02-23 00:00 ET
Quidel reported for 2022 q4
SEC form 6
2023-02-15 16:16 ET
Quidel published news for 2022 q4
SEC form 8
2023-02-15 00:00 ET
Quidel reported for 2022 q4
SEC form 6
2023-01-06 16:26 ET
Quidel published news for 2022 q4
SEC form 8
2023-01-06 00:00 ET
Quidel published news for 2022 q4
SEC form 6
2022-12-13 17:22 ET
Quidel published news for 2022 q3
SEC form 6
2022-12-05 07:48 ET
Quidel published news for 2022 q3
SEC form 10
2022-11-04 00:00 ET
Quidel reported for 2022 q3
SEC form 10
2022-11-03 20:40 ET
Quidel reported for 2022 q3
SEC form 6
2022-11-02 16:11 ET
Quidel published news for 2022 q3
SEC form 8
2022-11-02 00:00 ET
Quidel reported for 2022 q3
SEC form 6
2022-10-12 16:11 ET
Quidel published news for 2022 q3
SEC form 8
2022-10-12 00:00 ET
Quidel published news for 2022 q3
SEC form 6
2022-08-17 16:55 ET
Quidel published news for 2022 q2
SEC form 6
2022-08-10 17:27 ET
Quidel published news for 2022 q2
SEC form 10
2022-08-05 17:27 ET
Quidel reported for 2022 q2
SEC form 10
2022-08-05 00:00 ET
Quidel reported for 2022 q2
SEC form 6
2022-08-04 16:34 ET
Quidel published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Quidel reported for 2022 q2
SEC form 6
2022-07-07 17:02 ET
Quidel published news for 2022 q2
SEC form 6
2022-06-06 16:43 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:13 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:12 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:07 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:06 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:05 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:03 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:02 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:02 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:01 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:01 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 16:59 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 16:59 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 16:57 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 16:45 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 16:44 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 16:42 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 16:41 ET
Quidel published news for 2022 q1
SEC form 6
2022-05-27 09:10 ET
Quidel published news for 2022 q1